AdAlta (ASX:1AD) Insider Ownership : 0.00 % (As of Mar. 24, 2025)

View and export this data going back to 2016. Start your Free Trial

What is AdAlta Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AdAlta's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AdAlta's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AdAlta's Float Percentage Of Total Shares Outstanding is 0.00%.

AdAlta Insider Ownership Historical Data

The historical data trend for AdAlta's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta Insider Ownership Chart

AdAlta Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Insider Ownership

Get a 7-Day Free Trial

AdAlta Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Insider Ownership	Get a 7-Day Free Trial												-	-	-	-	-

AdAlta Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

AdAlta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Science Drive, La Trobe Institute for Molecular Science, Room 204, LIMS2, La Trobe University, Bundoora, VIC, AUS, 3086

Website

https://www.adalta.com.au

AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation protein and cell-based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.

AdAlta Headlines

No Headlines